TLR4 and inflammatory response: Levels of eight metabolites were 2.44–3.74 times greater following treatment with QFDYGs vs. QFDYDs, although both demonstrated significant protective effects against pulmonary inflammation through TLR4 signaling pathway modulation, gut microbiota restoration, and metabolic regulation.